2026 Northwest Allergy Forum (NWAF)
The NWAF is an annual educational conference hosted on alternate years by the Washington and Oregon Societies of Allergy, Asthma and Immunology. This year, the NWAF will be hosting by the WSSAAI. The conference is attended by allergists, Fellows in Training, physicians in related specialties as well as Residents, Medical Students and Nurses. The 2-day program with both local and national speakers will cover disease states such as urticaria, food allergy, asthma, angioedema, biologic therapies, and online advocacy.
Accreditation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of American College of Allergy, Asthma & Immunology and the Washington State Society of Allergy, Asthma & Immunology (WSSAAI). The American College of Allergy, Asthma & Immunology is accredited by the ACCME to provide continuing medical education for physicians.
Designation
The American College of Allergy, Asthma & Immunology (ACAAI) designates this live activity for a maximum of 9 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CBRN
The American College of Allergy, Asthma & Immunology (ACAAI) is a provider, approved by the California Board of Registered Nursing, Provider Number CEP17239, for 9 contact hours.
No commercial support was received for this activity.
Target Audience
Practicing allergists
Allied health professionals
Learning Objectives
At the conclusion of this activity learners should be able to…
1. Appraise current and emerging therapies, including oral and intralymphatic immunotherapy, in terms of safety, adherence, and long-term outcomes compared to strict avoidance.
2. Apply clinical practice guidelines to the management of patients with CSU.
3. Propose strategies for timely specialist referral, multidisciplinary collaboration, and patient education to optimize biologic use, adherence, and long-term asthma outcomes.
4. Consolidate evidence on the identification and management of uncontrolled and severe asthma, incorporating phenotype, endotype, and biomarker assessment to guide individualized treatment.
Course summary
- 9.00 AMA PRA Category 1 Credit™
- 9.00 Attendance
- 9.00 CBRN
WSSAAI: Northwest Allergy Forum
October 9-11, 2026
Hyatt at Olive 8 Seattle, WA
All Education Sessions to be held in Ballroom A, B
Exhibits and Coffee Breaks to be held in Ballroom C, D, E
Friday, October 9
5:00-6:00pm Registration, Exhibits & Welcome Reception
6:00-7:00pm Dinner Program
Operational Efficiency / Q&A - Kristina James, MD
brought to you by the Washington State Society of Allergy, Asthma and Immunology and the American College of Allergy, Asthma & Immunology
Saturday, October 10
6:30-7:50am Exhibits | Registration | Coffee Break
NWAF General Session
7:50-8:00am Welcome & Introduction – Albert Tsien, MD, WSSAAI
Session Moderator – Albert Tsien, MD, WSSAAI
8:00-9:00am Global Innovations and Breakthroughs in Urticaria Management / Q&A - Jonathan A. Bernstein, MD
9:00-10:00am Angioedema Without Itch / Q&A - Jonathan A. Bernstein, MD
10:00-10:30am Coffee Break | Exhibits
10:30-11:30am Asthma Inception: Clinical and Molecular Phenotypes in Early Life / Q&A - Matthew C. Altman, MD
11:30am-12:30pm Mechanisms and Predictors of Response (or Failure) to Biologic Therapies in Asthma and Allergy / Q&A - Matthew C. Altman, MD
12:30pm Adjourn
Sunday, October 11
7:00-8:00am Exhibits | Coffee Break
NWAF General Session
7:50-8:00am Welcome & Introduction
Session Moderator – Rahool Davé, MD, WSSAAI
8:00-9:00am The Latest in Treatment Options for Food Allergy / Q&A - Julie Wang, MD
9:00-10:00am From Bedside to Newsfeed: The Allergist’s Role in Combating Misinformation and Advancing Advocacy Online / Q&A - Payel Gupta, MD
10:00-10:30am Coffee Break | Exhibits
10:30-11:30am FPIES: Food Protein Induced Enterocolitis Syndrome / Q&A - Julie Wang, MD
11:30am-12:30pm Beyond the Waiting Room: How Allergists Can Use Social Media to Educate, Engage, and Build Trust / Q&A - Payel Gupta, MD
12:30pm Adjourn
All relevant financial relationships with ineligible companies have been mitigated.
Jonathan A Bernstein, MD – Speaker
Consultant: Astria, Allakos, Amgen, Apogee, AstraZeneca, Aquestive, Biocryst, Blueprint Medicines, Celldex Therapeutics, CSL Behring, Eli Lilly, Enanta, Fresenius Kabi, Genentech, GSK, Hikma Pharmaceuticals, Ionis, Incyte, Japanese Tobacco Company, Jasper, Johnson and Johnson, KalVista Pharmaceuticals, Kenvue, Kymeria, Kyowa Kirin, Labcorp, Lycia, Nasus, Neffy, Novartis, Nurix, Opella, Pfizer, Pharming, RAPT, Regeneron Pharmaceuticals Inc., Sanofi, Shire/Takeda, Teledoc, Yuhan
Researcher: Astria, ADARx, Allakos, Amgen, ARS, AstraZeneca, Biocryst, Blueprint Medicines, Celldex Therapeutics, Cogent, CSL Behring, Eli Lilly, Escient, Evommune, Fresenius Kabi, Genentech, GSK, Ionis, Incyte, Intellia, Jasper, Johnson and Johnson, KalVista Pharmaceuticals, Labcorp, Merck, Nasus, Novartis, Pfizer, Pharming, Regeneron Pharmaceuticals Inc., Sanofi, Shire/Takeda, TEVA, Yuhan
Speaker: CSL Behring, Kalvista, Novartis, Pharming
Rahool Davé, MD – Planner
Advisor: Cogent, Novartis, Sanofi
Consultant: Novartis, Sanofi
Speaker: AstraZeneca, GSK, Sanofi
T. Ted Song, MD – Planner
Speaker: ARS Pharma, AstraZeneca
Julie Wang, MD – Speaker
Independent contractor: DBV Technologies, GSK, Siolta
The following have no relevant financial relationships with ineligible companies to disclose.
Matthew C. Altman, MD – Speaker
Payel Gupta, MD – Speaker
Kristina James, MD – Speaker
Albert Tsien, MD – Planner, Moderator
Karol Anderson - Planner
Available Credit
- 9.00 AMA PRA Category 1 Credit™
- 9.00 Attendance
- 9.00 CBRN

Facebook
X
LinkedIn
Forward